Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05997810 · ClinicalTrials.gov registry record
Parathyroid Tumor Clonal Status
A clinical trial of Primary Hyperparathyroidism and Parathyroid Tumor, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 839
- Enrollment target
- 3
- Study locations
NCT05997810: Recruiting study of Primary Hyperparathyroidism and Parathyroid Tumor, sponsored by Washington University School of Medicine.
NCT05997810 is a study of Primary Hyperparathyroidism and Parathyroid Tumor that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 839 participants, above the 632-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (33% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05997810, a study of Primary Hyperparathyroidism and Parathyroid Tumor, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 839 participants
- Enrollment target
- 3
- Study locations
Study Summary
To define the frequency of monoclonal-X and polyclonal-X tumors in PHPT participants having parathyroidectomy (PTX) and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a multicenter cohort of patients having bilateral neck exploration (BNE) and PTX (primary objectives).
Primary Outcome
1\. Frequency of monoclonal-X versus polyclonal-X parathyroid tumors in patients with hyperparathyroid disorders.
Conditions Studied
Study Locations (3)
Alabama
- University of Alabama-Birmingham - Birmingham
California
- University of California-Department of Surgery - San Francisco
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2027-01 |
What NCT05997810 shows while recruiting
NCT05997810 is an observational study that tracks outcomes without assigning an intervention. The registered 839 participants enrollment target is mid-sized for trials with a published cap, above the 632-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (33% higher).
The record links to 2 conditions, with Primary Hyperparathyroidism appearing as the primary indexed condition, and to 0 interventions.
NCT05997810 reports a single indexed study location in Alabama, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05997810 about?
NCT05997810 is a clinical study titled "Parathyroid Tumor Clonal Status". To define the frequency of monoclonal-X and polyclonal-X tumors in PHPT participants having parathyroidectomy (PTX) and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a ...
What is the current status of trial NCT05997810?
This trial is currently recruiting. The enrollment target is 839 participants. The study started on 2023-04-11. Estimated completion is 2027-01.
What conditions does trial NCT05997810 study?
This clinical trial studies the following conditions: Primary Hyperparathyroidism, Parathyroid Tumor.
Who is sponsoring clinical trial NCT05997810?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05997810 being conducted?
This trial has 3 study locations across Alabama, California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Hyperparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
RECRUITING · Phase 4
-
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
RECRUITING
-
Natural History Study of Parathyroid Disorders
RECRUITING
-
Glycemic Control, Type II Diabetes, Parathyroidectomy
ACTIVE NOT RECRUITING
-
Object Assessment of Improvement in Non-Specific Symptoms After Parathyroidectomy for Primary Hyperparathyroidism
COMPLETED
-
Circulating miRNA in Primary Hyperparathyroidism
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI